$NTIP

NETWORK-1 TECHNOLOGIES, INC. (NTIP): Results of Operations and Financial Condition

NETWORK-1 TECHNOLOGIES, INC. (NTIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh99-1.htm PRESS RELEASE DATED AUGUST 6, 2026 Exhibit 99.1 FOR IMMEDIATE RELEASE Corey M. Horowitz, Chairman and CEO Network-1 Technologies, Inc. (917) 692-0000 NETWORK-1 REPORTS SECOND QUARTER 2026 RESULTS New Canaan, Connecticut — August 6, 2026 — Network-1 Technolog

Original reporting
Published Aug 10, 2026, 8:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$NTIP
Neutral
medium confidence
Mentioned
$NTIP
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NTIPNeutralMed
01

Why it matters

Q2 2026 results show continued lack of revenue, rising litigation-related operating expenses, and a first-half accounting gain tied to ILiAD’s financing. The filing also reiterates trial dates for two major matters, which can shift expected value of future licensing settlements.

02

Market read

This is a primary-source update on NTIP’s quarterly financial condition and the status of key patent cases, which can affect probability-weighted licensing outcomes.

03

What to watch

Traders may overweight the absence of revenue in the quarter, while underweighting that trial dates are now set for key portfolios, which can change probability-weighted settlement expectations.

Relevance 7/10Novelty 6/10Timing: filed Aug 10, 2026 after Q2 2026 results release (SEC 8-K)

Background

Network-1 Technologies is a patent monetization company pursuing multiple infringement cases across its M2M/IoT, HFT, and Cox portfolios.

Company-level read

Ticker impact

$NTIPNeutralMedium confidence
Context

NTIP reported Q2 2026 results with no revenue, higher litigation-related expenses, and a $1.052M ILiAD remeasurement gain in the first half of 2026.

Expected impact

Near-term sentiment likely hinges on whether traders view the ILiAD gain as non-recurring versus continued litigation-driven cash burn; stock reaction could be muted unless guidance or settlement signals emerge.

Evidence & confidence

The 8-K provides concrete financial line items (no revenue, operating expense increases, net loss) and specific litigation trial dates (Dec 7, 2026 for the Cox/Google matter; June 7, 2027 for Samsung), but it does not provide new settlement terms or revenue guidance.

Market effects

Highlights the patent-licensing business model’s earnings sensitivity to litigation outcomes and accounting treatment of investments.

No clear regional market spillover beyond US federal court litigation timelines.

Samsung-related infringement case keeps international tech counterparties in focus, but no direct global macro linkage is provided.

Counterpoint

The ILiAD gain and sizable cash/working capital suggest downside may be more about timing of licensing and litigation milestones than immediate solvency risk.

Key entities

  • Network-1 Technologies, Inc.

    Reported Q2 2026 financial results on Form 8-K, including no revenue, higher litigation expenses, and ongoing patent litigation timelines.

  • ILiAD Biotechnologies, Inc.

    Network-1’s investment was remeasured after ILiAD closed a $115M financing in February 2026, generating a $1.052M gain in Q1 2026.

  • Samsung Electronics Co., LTD

    Defendant in Network-1’s M2M/IoT patent infringement suit; trial scheduled for June 7, 2027.

  • Google and YouTube

    In Network-1’s Cox patent portfolio dispute, the Federal Circuit overturned a non-infringement judgment and remanded; trial scheduled for Dec 7, 2026.

Related articles

$RKLBHighAI 9/10

Rocket Lab revenue climbs 62% as backlog reaches record $2.36 billion

Rocket Lab reported Q2 revenue of $234.1 million, up 62% year over year, driven by product sales rising to $181.3 million. Gross profit increased to $84.6 million and gross margin to about 36%. Backlog hit a record $2.36 billion. The company forecast Q3 revenue of $250 million to $265 million and expects an adjusted EBITDA loss of $17 million to $23 million.

$JNJMed

Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?

Johnson & Johnson (JNJ) reported fiscal Q2 2026 sales of $25.31B (+6.6% YoY) and adjusted EPS of $2.90, both above estimates, and raised full-year guidance to a $101.1B midpoint and $11.68 adjusted EPS. Medtronic (MDT) posted its fastest annual revenue growth in a decade, with FY26 revenue $36.4B and adjusted revenue $36.3B. Article compares post-earnings positioning and risks.

$USNAMedAI 8/10

USANA Health Sciences Q2 Earnings Call Highlights

USANA Health Sciences (NYSE:USNA) reported Q2 updates including a $29 million preliminary non-cash goodwill impairment tied to its Hiya reporting unit and $9 million income tax expense on a $19 million pre-tax loss. Management cited about $30 million to $40 million top-line pressure and $4 million to $5 million margin pressure, plus a Rise packaging disruption. USANA ended with $169 million cash and no debt.